Today’s Price Action: Amicus Therapeutics, Inc. Stock Is Rising Now

Today's Price Action: Amicus Therapeutics, Inc. Stock Is Rising Now

The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a huge mover today! The stock increased 4.67% or $0.33 during the last trading session, hitting $7.4. About 1.84 million shares traded hands. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 13.48% since February 26, 2016 and is uptrending. It has outperformed by 3.06% the S&P500.
The move comes after 8 months positive chart setup for the $975.91 million company. It was reported on Oct, 1 by Barchart.com. We have $11.32 PT which if reached, will make NASDAQ:FOLD worth $517.23 million more.

Analysts await Amicus Therapeutics, Inc. (NASDAQ:FOLD) to report earnings on November, 1. They expect $-0.30 earnings per share, up 6.25% or $0.02 from last year’s $-0.32 per share. After $-0.40 actual earnings per share reported by Amicus Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -25.00% EPS growth.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings Coverage

Out of 7 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 5 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 71% are positive. Amicus Therapeutics has been the topic of 11 analyst reports since August 18, 2015 according to StockzIntelligence Inc. The firm has “Neutral” rating by Robert W. Baird given on Thursday, April 14. The stock has “Buy” rating given by Janney Capital on Tuesday, March 8. The company was maintained on Monday, October 5 by Leerink Swann. The stock has “Buy” rating given by Cowen & Co on Tuesday, September 1. Zacks downgraded the stock to “Buy” rating in Tuesday, August 18 report. Goldman Sachs initiated Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Wednesday, March 30 with “Neutral” rating. On Monday, August 31 the stock rating was maintained by Leerink Swann with “Buy”. Chardan Capital Markets downgraded Amicus Therapeutics, Inc. (NASDAQ:FOLD) rating on Wednesday, September 16. Chardan Capital Markets has “Neutral” rating and $17 price target. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) earned “Buy” rating by Bank of America on Wednesday, May 18. Chardan Capital Markets upgraded the stock to “Buy” rating in Monday, October 5 report.

According to Zacks Investment Research, “AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.”

Insitutional Activity: The institutional sentiment increased to 1.64 in Q2 2016. Its up 0.71, from 0.93 in 2016Q1. The ratio improved, as 20 funds sold all Amicus Therapeutics, Inc. shares owned while 25 reduced positions. 22 funds bought stakes while 52 increased positions. They now own 136.20 million shares or 2.45% more from 132.95 million shares in 2016Q1.
Blackrock Management Limited Liability Corporation accumulated 0% or 472,055 shares. Moreover, Northern has 0% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 1.44 million shares. Blackrock Grp holds 0% or 72,024 shares in its portfolio. Acuta Capital Prtn Limited owns 1.16 million shares or 3.05% of their US portfolio. Amalgamated Bank & Trust accumulated 13,453 shares or 0.01% of the stock. Blackrock Fund Advsrs accumulated 5.79M shares or 0.01% of the stock. The Pennsylvania-based Nationwide Fund Advsr has invested 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Jw Asset Management Ltd Liability Corp reported 20,000 shares or 0.09% of all its holdings. Cqs Cayman Limited Partnership last reported 0.67% of its portfolio in the stock. Brown Advisory Inc has 31,850 shares for 0% of their US portfolio. Proshare Advisors Ltd Llc accumulated 110,154 shares or 0.01% of the stock. Alliancebernstein Limited Partnership last reported 0.01% of its portfolio in the stock. Springbok Capital Mngmt Lc accumulated 0% or 5,700 shares. Fmr Ltd Liability Com accumulated 0.01% or 19.02M shares. Td Asset last reported 172,100 shares in the company.

Insider Transactions: Since June 2, 2016, the stock had 2 buys, and 6 insider sales for $7.63 million net activity. $477,360 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) was bought by Redmile Group – LLC on Friday, June 3. 1.10M shares were sold by PERCEPTIVE ADVISORS LLC, worth $7.49M. Do Hung also sold $175,000 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares. $146,412 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) was sold by Barth Jay on Wednesday, July 27. $115,050 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) was bought by Rosenberg Ellen. Baird William D III sold $164,075 worth of stock.

Another recent and important Amicus Therapeutics, Inc. (NASDAQ:FOLD) news was published by Seekingalpha.com which published an article titled: “Amicus Therapeutics: Key Catalysts Approaching” on September 19, 2016.

FOLD Company Profile

Amicus Therapeutics, Inc., incorporated on February 4, 2002, is a biopharmaceutical company. The Firm is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. The Company’s lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD). The Firm has completed two Phase III global registration studies (Study 011 and Study 012) of migalastat monotherapy. The Firm is also engaged in Phase III clinical development of a topical cream, SD-101, for the treatment of the genetic connective tissue disorder Epidermolysis Bullosa (EB). It has also initiated a clinical study in patients with Pompe disease, another LSD to investigate its treatment paradigm that consists of ATB200, which is an engineered recombinant human acid alpha-glucosidase (rhGAA) enzyme with an optimized carbohydrate structure to enhance uptake, co-administered with a pharmacological chaperone, AT2221, to improve activity and stability.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment